Containing AMR contribution from pharmaceutical effluent involving multi-stakeholders: Dr Anita Kotwani

  10 November 2020

From the environmental sector and specifically from the industry sector, the pharmaceutical industry manufacturing antibiotics play an important role in the development of AMR. The pharmaceutical sector is growing fast and is expected to be worth USD1.57 trillion by 2023. There is a huge increase in the use and manufacturing of antibiotics in the last decade or so. With the rise in antibiotics manufacturing, understandably there is a rise in pharmaceutical effluent generated by the industry. The effluents generated from antibiotic manufacturing units, both active pharmaceutical ingredient (API) and finished pharmaceutical product (FPP) contain antibiotic residues, though higher amounts of antibiotics are expected in the effluent of API manufacturing units. 

Further reading: ET Health World
Author(s): Anita Kotwani,
Clean Environment  
Back

OUR UNDERWRITERS

Unrestricted financial support by:

Antimicrobial Resistance Fighter Coalition

Bangalore Bioinnovation Centre

INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS

BD





AMR NEWS

Your Biweekly Source for Global AMR Insights!

Stay informed with the essential newsletter that brings together all the latest One Health news on antimicrobial resistance. Delivered straight to your inbox every two weeks, AMR NEWS provides a curated selection of international insights, key publications, and the latest updates in the fight against AMR.

Don’t miss out on staying ahead in the global AMR movement—subscribe now!

Subscribe

What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!

Keep me informed